title: Letter to the editor concerning first-line therapy with afatinib - an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations.
authors.affiliation: Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland.
authors.forename: Paweł
authors.initials: P
authors.lastname: Krawczyk
authors.affiliation: Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Powrózek
authors.affiliation: Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland.
authors.forename: Marcin
authors.initials: M
authors.lastname: Nicoś
authors.affiliation: Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland.
authors.forename: Janusz
authors.initials: J
authors.lastname: Milanowski